Triamcinolone Acetonide, Amlexanox and Tacrolimus as topical application for oral erosive lichen planus: Clinical effectiveness and evaluation

Abstract

Aim: Oral Lichen Planus (OLP), first described by Wilson E. in 1869, is a prevalent oral mucosal disease affecting the global population. The study evaluates and compares the clinical efficacy of various topical applications: Triamcinolone Acetonide 0.1% (TA1), Amlexanox 5% (TA2) and Tacrolimus 0.03% (TA3) in the treatment of OLP.
Materials and Methods: A study involving 90 patients aged 18-70 years enrolled in a randomized, single-blind, placebo-controlled clinical design enrolled them in three groups using three oral creams. Patients were monitored for allergic reactions and evaluated weekly for effectiveness and safety.
Results: Relative to baseline data, the acute sensation diminished by 31% after the first week, 57% after the second week, and 74% after the third week. The intra-group comparison of burning sensation scores was performed using the Wilcoxon matched-pairs signed rank test, a non-parametric statistical method. Compared to BL, there was a substantial decrease in burning sensation (P<0.001) during the first, second, and third weeks.
Conclusions: The research demonstrates that Amlexanox 5% oral paste, when used topically, markedly alleviates symptoms of OLP, diminishing the size of the erosive region and VAS scores within 28 days.